ASH Annual Meeting and Exposition | Conference

KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned

December 10th 2019

Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.

Acalabrutinib Benefit in CLL Sustained With Long-Term Follow-Up

December 10th 2019

Patients with relapsed/refractory chronic lymphocytic leukemia had ongoing benefits 42 months after starting treatment with the BTK inhibitor acalabrutinib.

CPI-0610 Shows Strong Efficacy Signals for Advanced Myelofibrosis

December 10th 2019

CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.

Patients with B-Cell Malignancies Experience Stable Disease on Vecabrutinib Therapy

December 10th 2019

Vecabrutinib, a reversible, noncovalent Bruton’s tyrosine kinase inhibitor, exhibited evidence of clinical activity in adults with B-cell malignancies without producing any grade ≥3 treatment-related adverse events.

Dr. Madduri on the Results of the CARTITUDE-1 Trial in Multiple Myeloma

December 9th 2019

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the results of the phase Ib/II CARTITUDE-1 trial of the BCMA-directed CAR T-cell therapy JNJ-4528 in patients with heavily pretreated relapsed/refractory multiple myeloma.

Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL

December 9th 2019

Benjamin L. Lampson, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, discusses preliminary safety and efficacy results from a phase II study of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Liso-Cel Continues to Show Promise in Relapsed/Refractory CLL/SLL

December 9th 2019

The CD19-directed CAR T-cell therapy lisocabtagene maraleucel showed promising clinical activity and manageable toxicity in heavily pretreated patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma, all of whom had progressed on ibrutinib.

Initial Higher-Dose Duvelisib Improves Responses in Relapsed/Refractory PTCL

December 9th 2019

Patients with relapsed/refractory peripheral T-cell lymphoma who received a higher initial dose of duvelisib at 75 mg BID had a higher overall response rate of 62% than those who received 25 mg BID.

Zanubrutinib Effective in CLL/SLL, Regardless of Del(17p) Status

December 9th 2019

The BTK inhibitor zanubrutinib continues to demonstrate high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of the presence of high-risk cytogenetics.

LOXO-305 Is Highly Effective in Heavily Pretreated B-cell Malignancies

December 9th 2019

More than half of patients with heavily pretreated B-cell malignancies responded to the noncovalent BTK inhibitor LOXO-305, including those with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors.

Early Steroid Use Reduces Risk of Cytokine Release Syndrome With Axi-Cel

December 9th 2019

Steroid use while cytokine release syndrome and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurologic events.

Lenalidomide Plus Obinutuzumab Achieves 100% ORR in Rituximab-Refractory Indolent Non-Hodgkin Lymphoma

December 9th 2019

The combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) elicited a 100% overall response rate in patients with relapsed indolent non-Hodgkin lymphoma that was refractory to rituximab (Rituxan).

Dr. Seymour on the 4-Year Update of the MURANO Trial in CLL

December 9th 2019

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the 4-year update of the phase III MURANO trial in chronic lymphocytic leukemia (CLL).

Dr. Abramson on Safety and Efficacy of Liso-Cel in Relapsed/Refractory Large B-Cell Lymphoma

December 9th 2019

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the pivotal safety and efficacy results from phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory large B-cell lymphoma.

Lenalidomide/Rituximab PFS Benefit Maintained in Elderly Subgroup With Indolent Non-Hodgkin Lymphoma

December 9th 2019

The combination of lenalidomide (Revlimid) and rituximab showed a 34% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma, although it was not found to be statistically significant.

Ibrutinib May Thwart PFS Decline in R/R Mantle Cell Lymphoma

December 9th 2019

In patients with relapsed mantle cell lymphoma, treatment with ibrutinib might mitigate a historical trend toward decreased progression-free survival with succeeding lines of therapy.

Liso-Cel Induces High Rate of Durable Responses in LBCL

December 9th 2019

CD19-directed CAR T-cell therapy induced a high rate of rapid and durable complete responses in patients with aggressive relapsed/refractory large B-cell lymphoma.

Novel Triplet Shows Early Promise for Pretreated CLL

December 8th 2019

The triplet of umbralisib, ublituximab, and venetoclax induced a complete remission rate of 44% as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia.

Triplet Regimen Induces High Rate of CR in R/R Follicular Lymphoma

December 8th 2019

The combination of polatuzumab-vedotin (Polivy), obinutuzumab (Gazyva), and lenalidomide (Revlimid) induced a high rate of durable responses in patients with relapsed/refractory follicular lymphoma.

Dr. Tam on Results of the CAPTIVATE Trial in CLL

December 8th 2019

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).